Pharmabiz

Chugai announces Roche to discontinue development of emugrobart in spinal muscular atrophy and FSHD

Chugai announces Roche to discontinue development of emugrobart in spinal muscular atrophy and FSHD: Tokyo Tuesday, March 24, 2026, 14:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd.
Pharmabiz

Japan MHLW grants marketing authorization to Bayer’s Eylea 8 mg to treat patients with macular edema following RVO

Japan MHLW grants marketing authorization to Bayer’s Eylea 8 mg to treat patients with macular edema following RVO: Berlin Tuesday, March 24, 2026, 13:00 Hrs [IST] The Ministry ...
Pharmabiz

Galderma receives US FDA approval for Restylane Contour for the correction of temple hollowing

Galderma receives US FDA approval for Restylane Contour for the correction of temple hollowing: Zug, Switzerland Tuesday, March 24, 2026, 18:00 Hrs [IST] Galderma, the pure-play d ...
Pharmabiz

Novartis to present new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

Novartis to present new data on early symptom relief and long-term control in complex skin diseases at AAD 2026: Basel Tuesday, March 24, 2026, 15:00 Hrs [IST] Novartis will prese ...
Pharmabiz

North India’s largest Bone Marrow Transplant Centre inaugurated at ShardaCare-Healthcity by Hon’ble Brajesh Pathak, deputy chief minister and MoHFW

North India’s largest Bone Marrow Transplant Centre inaugurated at ShardaCare-Healthcity by Hon’ble Brajesh Pathak, deputy chief minister and MoHFW: Our Bureau, Mumbai Tuesday ...
Pharmabiz

Enhertu approved in Japan as first tumour agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumours

Enhertu approved in Japan as first tumour agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumours: Tokyo Tuesday, March 24, 202 ...
Pharmabiz

Chugai receives Japanese approval for Lunsumio & Polivy combo therapy for additional indication of relapsed or refractory large B-cell lymphoma

Chugai receives Japanese approval for Lunsumio & Polivy combo therapy for additional indication of relapsed or refractory large B-cell lymphoma: Tokyo Tuesday, March 24, 2026, 11: ...
Pharmabiz

Tryfacta expands Federal and Defense health footprint with over $62 million in DHA MQS2-NG

Tryfacta expands Federal and Defense health footprint with over $62 million in DHA MQS2-NG: Our Bureau, Bengaluru Tuesday, March 24, 2026, 10:00 Hrs [IST] Tryfacta, Inc., a leadin ...
Pharmabiz

Pfizer and Valneva announce Lyme disease vaccine candidate demonstrates strong efficacy in phase 3 VALOR trial

Pfizer and Valneva announce Lyme disease vaccine candidate demonstrates strong efficacy in phase 3 VALOR trial: New York Tuesday, March 24, 2026, 12:00 Hrs [IST] Pfizer Inc. and V ...
Pharmabiz

Everest Medicines inks Asset Purchase Agreement with Corxel to develop and commercialize Cardamyst nasal spray in Greater China

Everest Medicines inks Asset Purchase Agreement with Corxel to develop and commercialize Cardamyst nasal spray in Greater China: Shanghai, China Tuesday, March 24, 2026, 16:00 Hrs ...
Pharmabiz

Mumbai Foot & Ankle Conference 2026 concludes successfully with dual conferences, global faculty, and advanced training

Mumbai Foot & Ankle Conference 2026 concludes successfully with dual conferences, global faculty, and advanced training: Our Bureau, Mumbai Tuesday, March 24, 2026, 15:45 Hrs [IST ...
Pharmabiz

Cogniverse 2026, Ivory brings clinical experts to advance brain health and early detection in India

Cogniverse 2026, Ivory brings clinical experts to advance brain health and early detection in India: Our Bureau, Bengaluru ...